Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026)
Lantheus Holdings (LNTH) reported Cash from Financing Activities of -$11.6 million for Q1 2026, up 36.2% year-over-year from -$8.5 million in Q1 2025, and up 88.47% quarter-over-quarter from -$100.8 million in Q4 2025.
Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Cash from Financing Activities data on file, last reported at -$11.6 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$11.6 million, up 36.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$310.0 million (down 158.52% YoY), and the FY2025 annual result was -$316.6 million, down 167.08% from the prior year.
- Cash from Financing Activities advanced to -$11.6 million in Q1 2026 per LNTH's latest filing, from -$100.8 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $317.8 million in Q4 2022 and troughed at -$103.7 million in Q4 2024.
- A 5-year average of -$8.7 million and a median of -$4.1 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 15235.24% in 2022, then sank 99507.07% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $317.8 million in 2022, then plunged by 100.14% to -$450000.0 in 2023, then tumbled by 22935.33% to -$103.7 million in 2024, then rose by 2.77% to -$100.8 million in 2025, then soared by 88.47% to -$11.6 million in 2026.
- Business Quant data shows LNTH's Cash from Financing Activities at -$11.6 million in Q1 2026, -$100.8 million in Q4 2025, and -$99.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | -11.62 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -77.88 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.62 Mn |
| Mar 31, 2026 | -11.62 Mn |
| Dec 31, 2025 | -100.79 Mn |
| Dec 31, 2025 | -100.79 Mn |
| Sep 30, 2025 | -99.17 Mn |
| Sep 30, 2025 | -99.17 Mn |
| Jun 30, 2025 | -98.41 Mn |
| Jun 30, 2025 | -98.41 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Dec 31, 2024 | -103.66 Mn |
| Dec 31, 2024 | -103.66 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 99,000.00 |
| Mar 31, 2024 | -16.85 Mn |
| Mar 31, 2024 | -16.85 Mn |
| Dec 31, 2023 | -450,000.00 |
| Dec 31, 2023 | -450,000.00 |